VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the Company’s wholly-owned subsidiary Optimi Labs Inc.


Previous articleTrauma and Vulnerability to Suggestion: Redefining How We Understand Consent
Next articlePT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic Conversations